0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CEACAM-6

CEACAM-6

Brief Information

Name:Carcinoembryonic antigen related cell adhesion molecule 6
Target Synonym:CEACAM6,CEA Cell Adhesion Molecule 6,CD66c,NCA,Carcinoembryonic Antigen Related Cell Adhesion Molecule 6,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 (Non-Specific Cross Reacting Antigen),Normal Cross-Reacting Antigen,Carcinoembryonic Antigen
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
CE6-H82E7 Human Biotinylated Human CEACAM-6 / CD66c Protein, His,Avitag™
CE6-H82E7-structure
CE6-H82E7-sds
CE6-H82E7-elisa_1
CE6-H5223 Human Human CEACAM-6 / CD66c Protein, His Tag
CE6-H5223-structure
CE6-H5223-sds
CE6-H5223-elisa_1

Part of Bioactivity data

CE6-H5223-ELISA
Human CEACAM-6, His TagHuman CEACAM-6, His Tag (Cat. No. CE6-H5223) ELISA bioactivity

Immobilized Human CEACAM-6, His Tag (Cat. No. CE6-H5223) at 10 μg/mL (100 μL/well) can bind Biotinylated Human CEACAM-8, His,Avitag (Cat. No. CE8-H82E9) with a linear range of 0.02-0.313 μg/mL (QC tested).

CE6-H82E7-ELISA
Biotinylated Human CEACAM-6, His,AvitagBiotinylated Human CEACAM-6, His,Avitag (Cat. No. CE6-H82E7) ELISA bioactivity

Immobilized Human CEACAM-8, His Tag (Cat. No. CE8-H5224) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CEACAM-6, His,Avitag (Cat. No. CE6-H82E7) with a linear range of 0.078-1.25 μg/mL (QC tested).

Synonym Name

CEACAM6,CD66c,CEAL,NCA

Background

Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) (CEACAM6) is also known as CD66c (Cluster of Differentiation 66c), CEAL, NCA, and is one of seven human CEACAM family members within the immunoglobulin superfamily. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM 6 contains one N-terminal V-type Ig-like domain (N domain), followed by two C2-type Ig-like domains. It shows considerable glycosylation, including (sialyl) LewisX, which mediates binding to E-selectin, galectins and some bacterial fimbrae. CEACAM-6 is expressed by granulocytes and their progenitors. It is also expressed by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
L-DOS-47 L-DOS-47 Phase 2 Clinical Helix Biopharma Pancreatic Neoplasms; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung Details
NEO-201 NEO-201 Phase 1 Clinical Precision Biologics, National Cancer Institute Cystadenocarcinoma, Mucinous; Carcinoma, Signet Ring Cell; Adenocarcinoma of Lung; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell Details

This web search service is supported by Google Inc.

totop